

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 27, 2007

**NEOSTEM, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**0-10909**  
(Commission File Number)

**22-2343568**  
(IRS Employer  
Identification No.)

**420 Lexington Avenue, Suite 450**  
**New York, New York**  
(Address of principal executive offices)

**10170**  
(Zip Code)

Registrant's telephone number, including area code: **(212) 584-4814**

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

NeoStem, Inc. (the "Company"), is furnishing presentation materials, included as Exhibit 99.1 to this current report and incorporated into this item by reference, which will be used by the Company at a healthcare conference on February 27, 2007.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit 99.1 Presentation

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

Dated: February 27, 2007

**NEOSTEM, INC.**

By: /s/ Catherine M. Vaczy

---

Catherine M. Vaczy  
Vice President and General Counsel

# NeoStem™

## Business Initiatives 2007



**Robin Smith, MD, MBA**  
CEO and Chairman of the Board

Molecular Medicine - Tri Conference  
February 27, 2007 - San Francisco, California



# FORWARD LOOKING STATEMENTS

---

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of NeoStem, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this presentation, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Additionally, statements concerning: the Company’s ability to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of such business are forward-looking statements. The Company’s ability to enter the adult stem cell arena and future operating results are dependent upon many factors including but not limited to (i) the Company’s ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company’s ability to build the management and human resources and infrastructure necessary to support the growth of its business and obtain appropriate state and other licenses; (iii) competitive factors and developments beyond the Company’s control; (iv) scientific and medical developments beyond the Company’s control including development in the potential therapeutic use of adult stem cells and (v) other risk factors discussed in the Company’s periodic filings with the Securities and Exchange Commission which are available for review at [www.sec.gov](http://www.sec.gov) under “Search for Company Filings.” You are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date hereof.

# 15 Minute Agenda

---

- Collections performed at company owned centers
- Processing and Storage (recurring revenue)
- Neostem today
- Vision for the future
- Questions

# Company Overview

---

## NeoStem:

- Pioneer the pre-disease collection, processing and storage of stem cells from adult donors that can be accessed for his or her own use for future medical treatment
- Provides a process that is safe and non-invasive
- Uses proprietary technology for the mobilization, processing and multiple use storage
- With re-infusion does not have the risk of rejection or graft vs. host disease
- Is well positioned to be the leading provider of autologous adult stem cells for therapeutic use in regenerative medicine
- Not caught in political policy, debate or religious controversy
- Publicly traded company: NEOI.OB



# Business Model

---

NeoStem generates revenue from:

- Collections
- Storage (recurring revenue)
- Utilization Fee (when cells are used)



# Market for NeoStem's Services

---

- By 2010, it is estimated that 39% of the U.S. population (over 110 mm people) will be 45 years of age or older.
- Anticipated rapid increase in age associated diseases.
- Millions of Americans suffer from diseases that can be treated with their own stem cells.
- "Bio-Insurance" - any adult who can afford it should consider banking their own stem cells for future use to treat disease.

# Stem Cell Therapeutics for Targeted Diseases

Disease	Prevalence*
Leukemia	208,080
Lymphoma & Multiple Myeloma	192,155
Coronary Artery Disease	6 million
Congestive Heart Failure	5 million (550,000 new cases per year)
Multiple Sclerosis	388,571
Lupus	1.4 million
Crohn's Disease	500,000
Rheumatoid Arthritis	2.1 million
Stroke	4.7 million stroke survivors (500,000 new cases per year)
Spinal Cord Injury	253,000
Diabetes	20.8 million
Sickle Cell Anemia	200,000
Parkinson	1.5 million
Osteoporosis	10 million
Breast Cancer	204,999 diagnosed new cases per year
<b>Total</b>	<b>53,000,000 Potential NeoStem Clients</b>




\*Miscellaneous Sources

# Adult Stem Cell Clinical Trials

- 196 Adult Autologous Stem Cell Clinical Trials

- 667 Adult Stem Cell Clinical Trials




# Adult Stem Cell Therapy in the News

---



**Dr. Burt treating Lupus with adult stems cells at Northwestern Hospital.**



# Company Chronology

---

Pre 2006	Phase III Medical – decided to exit legacy businesses and focus on stem cells
Jan '06	Phase III Medical acquired NeoStem
June-Aug '06	Raised \$3.75 million dollars through the sale of common stock and detachable warrants
Aug '06	Changed name from Phase III Medical to NeoStem, Inc.- Effected a 1:10 Reverse Stock Split
Sept '06	Signed first collection center agreement with Dr. Rothenberg –Encinitas, CA
Nov '06	Registration Statement Declared Effective
Nov '06	Started Collecting Adult Stem Cells
Dec '06	Neostem signs 5 year agreement with Hemacare for collection services
Jan '07	Signed strategic alliance with UTEK to identify licensing opportunities and expand IP portfolio
Jan-Feb '07	Raised \$2.5 million dollars through the sale of common stock and detachable warrants
Feb '07	Signed second collection agreement with Dr. Ivan Goldsmith in Las Vegas, NV



# “Go-to-Market” Strategy

---

## Drive General Awareness – Direct to Consumers

- The benefits of storing and using Adult Stem Cells is very attractive to the media
- Market as “Bio-Insurance”
- High net worth & educated consumer
- Family history of certain diseases
- Families that have stored umbilical cord blood (“Family Plan”)

## Collaborations with High Profile Medical Academic Institutions

- Involved with cutting edge research (research grants)
- Provide collection services for ongoing clinical trials
- Potential source of additional collection centers

## Partner with Physicians

- Wellness physicians
- Establish relationships with physicians in disparate specialties, such as cardiology, oncology and rheumatology.

# Scientific Advisory Board

---

## **Wayne A. Marasco, M.D., Ph.D.**

Chairman of Scientific Advisory Board. Associate Professor-Department of Cancer and Immunology & AIDS at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He will take the lead in expanding the Company's academic relationships and research collaborations.

# Scientific Advisory Board

---

## **Douglas W. Losordo, MD**

For many years a Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth's Medical Center in Boston, Dr. Losordo was recently appointed Professor of Medicine at Northwestern University and Director of the Feinberg Cardiovascular Research Institute and Program in Cardiovascular Regenerative Medicine. A Fellow or Member of many national professional organizations, he currently serves on committees of the American College of Cardiology, the American Diabetes Association and the American Society of Gene Therapy where he chairs the Cardiovascular Gene Therapy Committee. Dr. Losordo serves as Principal Investigator in many grant research projects and has published widely, contributing to more than 300 professional articles, abstracts and book chapters in recent years. He also serves on the Editorial Boards of numerous medical specialty journals including *Stem Cells*, *Vascular Medicine* and *Circulation Research*.



# Scientific Advisory Board

---

## Stephen D. Nimer, MD

Dr. Nimer is Professor of Medicine and Professor of Pharmacology at Weill Medical College of Cornell University. He also serves as Chief of Hematology Service and Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Nimer is a member of many national professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, and the International Society for Stem Cell Research. He serves as a Reviewer for major medical journals, including the *New England Journal of Medicine* and the *Journal of the American Medical Association (JAMA)* among many others. He serves on numerous national and international Grant Review Committees and is a prominent invited speaker at conferences on his areas of expertise. He has authored or co-authored nearly 200 peer-reviewed papers, reviews, editorials and textbook chapters, primarily focused on issues concerning hematology and oncology.

# Advisory Board

---

## **Ron Rothenberg MD, FACEP**

Dr. Rothenberg is a Fellow of the American College of Emergency Physicians (FACEP) and is the founder of the California HealthSpan Institute in Encinitas, California. He was the 10th M.D. in the world to become fully board certified by the American Board of Anti-Aging Medicine. A graduate of Columbia University, College of Physicians and Surgeons, and a specialist in Emergency Medicine at Los Angeles County-USC Medical Center, he has served as Clinical Professor of Preventive and Family Medicine at the UCSD School of Medicine Clinical Facility. He is currently Attending Physician at Scripps Memorial Hospital in Encinitas.

# Additional Company Initiatives

---

- Develop strategic initiatives with
  - Cord blood companies
  - Tissue banks
  - Pharmaceutical companies
- Academic institutions for licensing opportunities and build out of collection centers
- Partnerships with executive health programs, medical spas and first responder groups
- Expand intellectual property portfolio within the stem cell arena
- Grant applications to National Institutes of Health and others
- Formation of Adult Stem Cell Foundation

# Summary

---

- NeoStem has the first to market advantage in the collection and storage of stem cells extracted from adults.
- NeoStem represents a high growth opportunity in a large growing market.
- NeoStem is well positioned with industry leaders and academic institutions.
- NeoStem has an attractive valuation compared to other stem cell related companies and is not capital intensive. There are 26,551,213 shares of common stock outstanding at February 23, 2007.

# Questions